Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: Twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study

Journal of Endovascular Therapy

Volumn 18, Issue 5, 2011, Pages 613-623

  Dake, Michael D ^a   Scheinert, Dierk ^b   Tepe, Gunnar ^c   Tessarek, Jörg ^d   Fanelli, Fabrizio ^e   Bosiers, Marc ^f   Ruhlmann, Christof ^g   Kavteladze, Zaza ^h   Lottes, Aaron E ⁱ   Ragheb, Anthony O ⁱ   Zeller, Thomas ^j  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Park Hospital   (Germany)

^c Klinikum Rosenheim   (Germany)

^d ST BONIFATIUS HOSPITAL   (Germany)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f St Blasius Hospital   (Belgium)

^g Gemeinschaftspraxis   (Germany)

^h Endosurgery and Lithotripsy Center   (Russian Federation)

ⁱ Med Institute Inc Lafayette   (United States)

^j UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

more..

Author keywords

Drug eluting stent; In stent stenosis; Paclitaxel eluting stent; Peripheral vascular disease; Popliteal artery; Restenosis; Stenosis; Superficial femoral artery

Indexed keywords

NITINOL; PACLITAXEL; UNCLASSIFIED DRUG; ZILVER PTX;

ABOVE THE KNEE POPLITEAL ARTERY STENOSIS; ABSENCE OF SIDE EFFECTS; ADULT; ANKLE BRACHIAL INDEX; ARTERY OCCLUSION; ARTICLE; CLINICAL EFFECTIVENESS; DISEASE SEVERITY; DRUG ELUTING STENT; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; GRAFT FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; IN-STENT RESTENOSIS; KIDNEY FAILURE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT SAFETY; POPLITEAL ARTERY; PRIORITY JOURNAL; REVASCULARIZATION; STENT FRACTURE; SUPERFICIAL FEMORAL ARTERY; SUPERFICIAL FEMORAL ARTERY STENOSIS; SURVIVAL RATE; VASCULAR PATENCY; WALKING; WALKING SPEED;

AGED; ALLOYS; ARTERIAL OCCLUSIVE DISEASES; CANADA; CARDIOVASCULAR AGENTS; CONSTRICTION, PATHOLOGIC; DISEASE-FREE SURVIVAL; DRUG-ELUTING STENTS; ENDOVASCULAR PROCEDURES; EUROPE; FEMALE; FEMORAL ARTERY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PACLITAXEL; POPLITEAL ARTERY; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; RECOVERY OF FUNCTION; RECURRENCE; REPUBLIC OF KOREA; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 80054713807     PISSN: 15266028     EISSN: 15451550     Source Type: Journal    
DOI: 10.1583/11-3560.1     Document Type: Article

References (42)

1. Hunink MG, Wong JB, Donaldson MC, et al. Patency results of percutaneous and surgical revascularization for femoropopliteal arterial disease. Med Decis Making. 1994;14:71-81. (Pubitemid 24032684)
2. Goshima KR, Mills JL, Hughes JD. A new look at outcomes after infrainguinal bypass surgery: traditional reporting standards systematically underestimate the expenditure of effort required to attain limb salvage. J Vasc Surg. 2004;39:330-335. (Pubitemid 38174314)
3. Minar E, Pokrajac B, Maca T, et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation. 2000;102:2694-2699.
4. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg. 2000;31:S1-S296.
5. Rocha-Singh KJ, Jaff MR, Crabtree TR, et al. Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease. Catheter Cardiovasc Interv. 2007;69:910-919. (Pubitemid 46867500)
6. Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354:1879-1888. (Pubitemid 43872689)
7. Krankenberg H, Schlüter M, Steinkamp HJ, et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST). Circulation. 2007;116:285-292. (Pubitemid 47196564)
8. Zeller T, Tiefenbacher C, Steinkamp HJ, et al. Nitinol stent implantation in TASC A and B superficial femoral artery lesions: the Femoral Artery Conformexx Trial (FACT). J Endovasc Ther. 2008;15:390-398.
9. Bosiers M, Torsello G, Gissler HM, et al. Nitinol stent implantation in long superficial femoral artery lesions: 12-month results of the DURABILITY I study. J Endovasc Ther. 2009;16:261-269.
10. Mewissen MW. Stenting in the femoropopliteal arterial segment. Tech Vasc Interv Radiol. 2005;8:146-149. (Pubitemid 44038934)
11. Nikanorov A, Smouse HB, Osman K, et al. Fracture of self-expanding nitinol stents stressed in vitro under simulated intravascular conditions. J Vasc Surg. 2008;48:435-440.
12. Scheinert D, Scheinert S, Sax J, et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol. 2005;45:312-315. (Pubitemid 40094743)
13. Axel DI, Kunert W, Göggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation. 1997;96: 636-645. (Pubitemid 27329445)
14. Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358:689-699. (Pubitemid 351240748)
15. Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in femoropopliteal arteries paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118:1358-1365.
16. Rutherford RB, Becker GJ. Standards for evaluating and reporting the results of surgical and percutaneous therapy for peripheral arterial disease. J Vasc Interv Radiol. 1991;2:169-174.
17. Hiatt WR, Hirsch AT, Regensteiner JG, et al. Clinical trials for claudication: assessment of exercise performance, functional status, and clinical end points. Circulation. 1995;92:614-621.
18. Jaff M, Dake M, Popma J, et al. Standardized evaluation and reporting of stent fractures in clinical trials of noncoronary devices. Catheter Cardiovasc Interv. 2007;70:460-462. (Pubitemid 350194998)
19. Popma JJ, Tiroch K, Almonacid A, et al. A qualitative and quantitative angiographic analysis of stent fracture late following sirolimus eluting stent implantation. Am J Cardiol. 2009;103:923-929.
20. Cejna M, Thurnher S, Illiasch H, et al. PTA versus Palmaz stent placement in femoropopliteal artery obstructions: a multicenter prospective randomized study. J Vasc Interv Radiol. 2001;12:23-31. (Pubitemid 32097991)
21. Deutschmann HA, Schedlbauer P, Bérczi V, et al. Placement of Hemobahn stent-grafts in femoropopliteal arteries: early experience and midterm results in 18 patients. J Vasc Interv Radiol. 2001;12:943-949. (Pubitemid 32756864)
22. Lugmayr HF, Holzer H, Kastner M, et al. Treatment of complex arteriosclerotic lesions with nitinol stents in the superficial femoral and popliteal arteries: a midterm follow-up. Radiology. 2002;222:37-43. (Pubitemid 34031461)
23. Duda SH, Pusich B, Richter G, et al. Sirolimuseluting stents for the treatment of obstructive superficial femoral artery disease. Circulation. 2002;106:1505-1509.
24. Duda SH, Bosiers M, Lammer J, et al. Sirolimuseluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol. 2005;16:331-338. (Pubitemid 40354849)
25. Ansel GM, Bottie CF, George BS, et al. IntraCoil Femoralpopliteal Stent Trial Investigators. Clinical results for the training phase roll-in patients in the IntraCoil femoralpopliteal stent trial. Catheter Cardiovasc Interv. 2002;56:443-449. (Pubitemid 34809018)
26. Duda SH, Bosiers M, Lammer J, et al. Drugeluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther. 2006;13:701-710. (Pubitemid 44907633)
27. Lammer J, Bosiers M, Zeller T, et al. First clinical trial of nitinol self-expanding everolimuseluting stent implantation for peripheral arterial occlusive disease. J Vasc Surg. 2011;54:394-401.
28. Murphy JG, Schwartz RS, Edwards WD, et al. Percutaneous polymeric stents in porcine coronary arteries. Initial experience with polyethylene terephthalate stents. Circulation. 1992;86:1596-1604.
29. van der Giessen WJ, Lincoff AM, Schwartz RS, et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation. 1996;94:1690-1697. (Pubitemid 26320276)
30. Otsuka Y, Chronos NA, Apkarian RP, et al. Scanning electron microscope analysis of defects in polymer coatings of three commercially available stents: comparison of BiodivYsio, Taxus and Cypher stents. J Invasive Cardiol. 2007;19:71-76.
31. Basalus MW, Ankone MJ, van Houwelingen GK, et al. Coating irregularities of durable polymer-based drug-eluting stents as assessed by scanning electron microscopy. Eurointervention. 2009;5:157-165.
32. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004;109:701-705. (Pubitemid 38222887)
33. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193-202. (Pubitemid 43929240)
34. Creel CJ, Lovich MA, Edelman ER. Arterial paclitaxel distribution and deposition. Circ Res. 2000;86:879-884. (Pubitemid 30246985)
35. Levin AD, Vukmirovic N, Hwang CW, et al. Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc Natl Acad Sci USA. 2004;101:9463-9467. (Pubitemid 38812897)
36. Dake MD, Van Alstine WG, Zhou Q, et al. Polymer-free paclitaxel-coated Zilver PTX stents - evaluation of pharmacokinetics and comparative safety in porcine arteries. J Vasc Interv Radiol. 2011;22:603-610.
37. Hong MK, Mintz GS, Lee CW, et al. Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: a serial volumetric intravascular ultrasound analysis from the Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT). Circulation. 2003;107:517-520. (Pubitemid 36176797)
38. Gershlick A, De Scheerder I, Chevalier B, et al. Inhibition of restenosis with a paclitaxeleluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation. 2004;109: 487-493. (Pubitemid 38168511)
39. Schillinger M, Sabeti S, Dick P, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation. 2007;115:2745-2749. (Pubitemid 46842791)
40. Laird JR, Katzen BT, Scheinert D, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3:267-276.
41. Ferreira M, Lanziotti L, Monteiro M, et al. Superficial femoral artery recanalization with self-expanding nitinol stents: long-term followup results. Eur J Vasc Endovasc Surg. 2007;34:702-708. (Pubitemid 350056379)
42. Schlager O, Dick P, Sabeti S, et al. Longsegment SFA stenting-the dark sides: in-stent restenosis, clinical deterioration, and stent fractures. J Endovasc Ther. 2005;12:676-684. (Pubitemid 43100925)